Thanks G-star, Biel is doing a much better job of communicating with shareholders now with a bimonthly newsletter...which they indicated they would be doing. Walmart discussions went well! Go Biel$$$
The Company is in discussions with two major organizations to rollout the RecoveryRx product in the US. Additionally, we are working to list the product with three major drug wholesalers (McKesson Corporation, Cardinal Health and Smith Drug).
>>>The neck study directly compares the effectiveness of ActiPatch to that of prescription NSAID pills. Subjects were randomly assigned either to receive the standard of care treatment (cox-2 inhibitor) or ActiPatch. Interim results demonstrate that the ActiPatch is statistically significantly superior to the prescription NAID drug in reducing neck pain. <<<
That should do it!!! Better than those liver damaging side affected pills (cox-2 inhibitors). But WE knew that already, didn't we? Hopefully this third part of body trial (what FDA wanted) will get us that all important FULL CLEARANCE!!